Update: SKP-2075/SKP-2076: future stars aligning
We recently attended Skyepharma’s capital markets day (CMD). Flutiform continues to post strong revenues, contributing directly to margins and underpinning strong growth in cash from operations. Post the CMD we have higher conviction for the potential mid- to long-term contributions from the respiratory assets in development, in particular the ground-breaking SKP-2075 for COPD/smoking asthma with headline Phase II data due in 2017 and SKP 2076, the triple therapy for asthma, which has potential for early partnering. At this stage we maintain our current forecasts but highlight that our 377p/share valuation looks conservative, particularly as we envisage the mid- to long-term earnings story unfolding.Skyland Petroleum is engaged in the licensing of copyright for feature films.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.